(SILVER SPRING, Md.) -- The U.S. Food and Drug Administration has approved an umbilical cord blood product for use in treating patients who require hematopoietic stem cell transplant procedures, according to a report in Medpage Today.
FDA officials say the product "Hemacord" is the first of its kind, and will be used to treat patients with disorders affecting the blood-forming system.
"The use of cord blood hematopoietic progenitor cell therapy offers potentially life-saving treatment options for patients with these types of disorders," Dr. Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research, said in a statement.
The use of Hemacord, manufactured by the New York Blood Center, should be monitored closely, according to the FDA. Risks associated with the product include graft-versus-host disease, engraftment syndrome, graft failure, and infusion reactions.
FDA officials say Hemacord will be used in treating patients suffering from blood cancer and inherited metabolic and immune system disorders.
Copyrihgt 2011 ABC News Radio